Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Protein Arginine Methyltransferase 1 (PRMT1) Suppresses The Differentiation of Germinal Centre B Cells and B Cell Lymphoma

FY 2021-22

Summary
Our natural defence against disease-causing germs is known as the immune system. The immune system is constantly protecting our bodies from disease-causing agents such as bacteria and viruses. To fight disease-causing agents, the immune system produces molecules called antibodies. Antibodies specifically recognize germs to stop them from causing disease. The production of antibodies is carried out by a group of cells called B cells. B cells function as tiny antibody-producing factories, constantly generating antibodies that can bind and eliminate germs before they make us sick. The gene, PRMT1protein arginine methyltransferase 1is a mediator of antibody production. PRMT1 controls the activity of our cells by modifying the chemical structure of cellular molecules. PRMT1 is known to help B cells release antibodies against germs. However, the mechanism by which PRMT1 acts within B cells is unclear. Recently, PRMT1 was shown to be deregulated in B cell cancersa disease in which B cells divide uncontrollably and cause damage to our bodies. Importantly, the de-regulation of PRMT1 in B cell cancers is associated with poor clinical outcomes. Yet, the role of PRMT1 in B cell cancers is poorly studied. Thus, how PRMT1 functions in B cells under normal and diseased states requires further investigation. This project aims to determine the function of PRMT1 in B cells under normal and diseased states using advanced techniques in molecular biology and immunology. This project will illuminate the role of PRMT1 to antibody-mediated immunity. Furthermore, this research project will reveal the role of PRMT1 in cancers arising from B cells themselves and will rationalize the use of therapies that specifically target PRMT1to treat B cell cancers.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
466516
Name
Slattery Michael
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Protein Arginine Methyltransferase 1 (PRMT1) Suppresses The Differentiation of Germinal Centre B Cells and B Cell Lymphoma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibodies; B Cells; Cancer; Cancer Treatment; Immunity; Infection; Lymphoma
Abstract
Our natural defence against disease-causing germs is known as the immune system. The immune system is constantly protecting our bodies from disease-causing agents such as bacteria and viruses. To fight disease-causing agents, the immune system produces molecules called antibodies. Antibodies specifically recognize germs to stop them from causing disease. The production of antibodies is carried out by a group of cells called B cells. B cells function as tiny antibody-producing factories, constantly generating antibodies that can bind and eliminate germs before they make us sick. The gene, PRMT1protein arginine methyltransferase 1is a mediator of antibody production. PRMT1 controls the activity of our cells by modifying the chemical structure of cellular molecules. PRMT1 is known to help B cells release antibodies against germs. However, the mechanism by which PRMT1 acts within B cells is unclear. Recently, PRMT1 was shown to be deregulated in B cell cancersa disease in which B cells divide uncontrollably and cause damage to our bodies. Importantly, the de-regulation of PRMT1 in B cell cancers is associated with poor clinical outcomes. Yet, the role of PRMT1 in B cell cancers is poorly studied. Thus, how PRMT1 functions in B cells under normal and diseased states requires further investigation. This project aims to determine the function of PRMT1 in B cells under normal and diseased states using advanced techniques in molecular biology and immunology. This project will illuminate the role of PRMT1 to antibody-mediated immunity. Furthermore, this research project will reveal the role of PRMT1 in cancers arising from B cells themselves and will rationalize the use of therapies that specifically target PRMT1to treat B cell cancers.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Slattery, Michael
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~